Clinical trial
Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line…
NCT00469443 · Hellenic Oncology Research Group, Other · Completed
Key facts
| NCT number | NCT00469443 |
|---|---|
| Title | Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC |
| Official title | A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer |
| Lead sponsor | Hellenic Oncology Research Group, Other |
| Collaborators | University Hospital of Crete |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Irinotecan, 5-Fluorouracil, Leucovorin, Capecitabine, Bevacizumab |
| Enrollment | 330 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | May 4, 2007 |
| Last update posted | Aug 19, 2010 |
| Countries | Greece |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: